Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 7-0963, Iss. 3, 2015-09 ,pp. : 777-787

John Wiley & Sons Inc

Access to resources Recommend Favorite

Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 2, 2015-02 ,pp. : 484-493

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1082-1090

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy of a health‐related quality‐of‐life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1091-1094

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 114-123

John Wiley & Sons Inc

Access to resources Recommend Favorite